Capital Expenditures - Prostatype Genomics AB (STO:PROGEN) - Alpha Spread
P

Prostatype Genomics AB
STO:PROGEN

Watchlist Manager
Prostatype Genomics AB
STO:PROGEN
Watchlist
Price: 0.018 SEK -5.26% Market Closed
Market Cap: 17.8m SEK
Have any thoughts about
Prostatype Genomics AB?
Write Note

Prostatype Genomics AB
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Prostatype Genomics AB
Capital Expenditures Peer Comparison

Comparables:
BIOG B
BONEX
VITR
SOBI
BIOA B

Competitive Capital Expenditures Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
P
Prostatype Genomics AB
STO:PROGEN
Capital Expenditures
-kr8.6m
CAGR 3-Years
-38%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biogaia AB
STO:BIOG B
Capital Expenditures
-kr48.6m
CAGR 3-Years
-45%
CAGR 5-Years
-29%
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Capital Expenditures
-kr8.3m
CAGR 3-Years
-62%
CAGR 5-Years
-29%
CAGR 10-Years
N/A
Vitrolife AB
STO:VITR
Capital Expenditures
-kr142m
CAGR 3-Years
-68%
CAGR 5-Years
-15%
CAGR 10-Years
N/A
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Capital Expenditures
-kr1.7B
CAGR 3-Years
24%
CAGR 5-Years
29%
CAGR 10-Years
-42%
BioArctic AB
STO:BIOA B
Capital Expenditures
-kr7.4m
CAGR 3-Years
16%
CAGR 5-Years
-12%
CAGR 10-Years
N/A

See Also

What is Prostatype Genomics AB's Capital Expenditures?
Capital Expenditures
-8.6m SEK

Based on the financial report for Dec 31, 2023, Prostatype Genomics AB's Capital Expenditures amounts to -8.6m SEK.

What is Prostatype Genomics AB's Capital Expenditures growth rate?
Capital Expenditures CAGR 3Y
-38%

The average annual Capital Expenditures growth rates for Prostatype Genomics AB have been -38% over the past three years .

Back to Top